Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ-0,39
KB0,43
PKN121121,70,75
Msft1,16
IBM0,73
DCX68,3368,36-0,84
PFE0,50
21.10.2017 2:10:00
Indexy online
AD Index online
select
AD Index online
 

  • 20.10.2017 22:00:00
Adamis Pharma (NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
5,35 1,90 0,10 1 188 315
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 22.10.2017
Popis společnosti
Obecné informace
Název společnostiAdamis Pharmaceuticals Corp
TickerADMP
Kmenové akcie:Ordinary Shares
RICADMP.O
ISINUS00547W2089
Prioritní akcieConv. Pref. Shrs Series A
Prioritní akciePreference Shares Series A2
Poslední známé roční výsledky31.12.2016
Poslední známé čtvrtletní výsledky30.6.2017
Počet zaměstnanců k 31.12.2016 14
Akcie v oběhu k 14.8.2017 31 351 334
Počet akcionářů k 31.12.2016 93
MěnaUSD
Kontaktní informace
Ulice11682 El Camino Real Ste 300
MěstoSAN DIEGO
PSČ92130-2092
ZeměUnited States
Kontatní osobaMark Gundy
Funkce kontaktní osobyIR Contact Officer
Telefon18 589 972 400
Fax13026365454
Kontatní telefon19 722 401 873

Business Summary: Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company's product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe (PFS), APC-5000 dry powder inhaler (DPI), APC-1000 and APC-2000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300. The Company's lead product candidate, the Epinephrine Injection USP 1:1000 0.3 milligram Pre-filled Single Dose Syringe, or the Epinephrine PFS, is a pre-filled syringe designed to deliver a premeasured 0.3 milligrams dose of epinephrine for the treatment of anaphylaxis. The Company also has licensed vaccine technology called somatic transgene immunization (STI) technology.
Financial Summary: BRIEF: For the six months ended 30 June 2017, Adamis Pharmaceuticals Corp revenues increased from $1.9M to $6.8M. Net loss decreased 11% to $10.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development decrease of 61% to $2.7M (expense), Interest Income increase from $0K to $9K (income).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Pharmaceuticals - NEC
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
NAICSInVitro Diagnostic Substance Manufacturing
SICPharmaceutical Preparations
SICPharmaceutical Preparations
SICCommercial Physical Research
SICDiagnostic Substances



  • Poslední aktualizace: 22.10.2017
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Independent Chairman of the BoardRichard Williams7125.8.2014
President, Chief Executive Officer, DirectorDennis Carlo711.4.20091.4.2009
Chief Financial Officer, Vice President - FinanceRobert Hopkins541.4.20091.4.2009
Senior Vice President - Corporate Development, DirectorDavid Marguglio441.4.2009
Vice President - OperationsKaren Daniels62
Vice President - Commercial OperationsGus Fernandez5415.4.201515.4.2015
Vice President - ResearchThomas Moll49